ICER releases evidence report on acute treatments for migraine

10 January 2020 - Lasmiditan, rimegepant, and ubrogepant all perform better than placebo, but evidence is not adequate to distinguish among ...

Read more →

Human medicines: highlights of 2019

9 January 2020 - EMA has published a review of its key recommendations in 2019 on the authorisation and safety ...

Read more →

ICER issues final report and policy recommendations on JAK inhibitors for rheumatoid arthritis

9 January 2020 - Despite upadacitinib reaching common thresholds for cost-effectiveness when compared to adalimumab, the independent appraisal committee’s votes on ...

Read more →

Price disclosure 2020 April cycle outcomes summary

18 December 2019 - The summary of price disclosure price reductions for the 2020 April Cycle has now been published. ...

Read more →

Proposal to decline inactive funding applications

17 December 2019 - To help make its decision-making process clearer, PHARMAC is seeking feedback on a proposal to make decisions ...

Read more →

Report on the collection of under co-payment data 2018-19

17 December 2019 - The report on the collection of under co-payment data 2018-19 is now available. ...

Read more →

PBAC Public Summary Documents - August 2019 intracycle meeting

13 December 2019 - The Public Summary Document for a review into antibiotics on the PBS from the August 2019 ...

Read more →

PBS expenditure and prescriptions report 2018-19

13 December 2019 - The PBS Expenditure and Prescriptions Report 1 July 2018 to 30 June 2019 is now available. ...

Read more →

SMC - December 2019 decisions

9 December 2019 - The Scottish Medicines Consortium, which advises on newly licensed medicines for use by NHSScotland, has today ...

Read more →

ICER issues final report and policy recommendations for add-on therapies to treat type 2 diabetes

9 December 2019 - Oral GLP-1 semaglutide achieves commonly cited thresholds for cost-effectiveness but is less cost-effective than SGLT-2 competitor empagliflozin. ...

Read more →

EMA publishes agenda for 9-12 December CHMP meeting

9 December 2019 - The EMA has published a draft agenda for this week's CHMP meeting. ...

Read more →

ICER releases evidence report on JAK inhibitors to treat rheumatoid arthritis

26 November 2019 - Using adalimumab as the comparator, upadacitinib’s value-based price benchmark is between $44,000-$45,000 per year; at December 9 ...

Read more →

PBAC Public Summary Documents - July 2019 meeting

15 November 2019 - The Public Summary Documents (first time rejections and deferrals) from the July 2019 PBAC meeting are now ...

Read more →

Drug makers fight Trump appellate bid to restore rule exposing drug prices in TV ads

14 November 2019 - A Trump administration requirement that drug companies include their products’ list prices in TV ads is ...

Read more →

NICE during the pre-election period

12 November 2019 - As a public body, NICE is required to follow civil service principles on communicating during the lead ...

Read more →